Cited by 555

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

The biology and treatment of EML4-ALK non-small cell lung cancer

Open access

Sasaki, Takaaki, Rodig, Scott J., Chirieac, Lucian R., Jänne, Pasi A.·2010·European Journal of Cancer

DOI 10.1016/j.ejca.2010.04.002

Open this paper in CoChat — free account

Abstract

The fusion between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) has recently been identified in a subset of non-small cell lung cancers (NSCLCs). EML4-ALK is most often detected in never smokers with lung cancer and has unique pathologic features. EML4-ALK is oncogenic both in vitro and in vivo and ALK kinase inhibitors are quite effective in pre-clinical model systems. More recently ALK inhibitors have entered clinical development and remarkably clinical efficacy has been observed in NSCLC patients harbouring EML4-ALK translocations. This review will focus on the biology, clinical characteristics, diagnosis and treatment of EML4-ALK NSCLC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2010.04.002

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,870
Self-citation
Lung cancer in never smokers — a different disease
Sun, S., Schiller, J. H., & Gazdar, A. F. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2190 · Cited by 1,608
The global burden of cancer: priorities for prevention
Thun, M. J., DeLancey, J. O., Center, M. M., Jemal, A., & Ward, E. M. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp263 · Cited by 1,091
EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
Koivunen, J. P., Mermel, C., Zejnullahu, K., Murphy, C., Lifshits, E., Holmes, A. J., Choi, H. G., Kim, J., Chiang, D., Thomas, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0168 · Cited by 993
The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS
Wong, D. W., Leung, E. L., So, K. K., Tam, I. Y., Sihoe, A. D., Cheng, L., Ho, K., Au, J. S., Chung, L., Pik Wong, M., et al. (2009) · Cancer · doi:10.1002/cncr.24181 · Cited by 719
KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
Takeuchi, K., Choi, Y. L., Togashi, Y., Soda, M., Hatano, S., Inamura, K., Takada, S., Ueno, T., Yamashita, Y., Satoh, Y., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3248 · Cited by 717
Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas
Shigematsu, H., Takahashi, T., Nomura, M., Majmudar, K., Suzuki, M., Lee, H., Wistuba, I. I., Fong, K. M., Toyooka, S., Shimizu, N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4235 · Cited by 678
Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population
Rodig, S. J., Mino-Kenudson, M., Dacic, S., Yeap, B. Y., Shaw, A., Barletta, J. A., Stubbs, H., Law, K., Lindeman, N., Mark, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0802 · Cited by 678
Self-citation
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
Christensen, J. G., Zou, H. Y., Arango, M. E., Li, Q., Lee, J. H., McDonnell, S. R., Yamazaki, S., Alton, G. R., Mroczkowski, B., & Los, G. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0365 · Cited by 649
A mouse model for EML4-ALK -positive lung cancer
Soda, M., Takada, S., Takeuchi, K., Choi, Y. L., Enomoto, M., Ueno, T., Haruta, H., Hamada, T., Yamashita, Y., Ishikawa, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805381105 · Cited by 512
Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts
Takeuchi, K., Choi, Y. L., Soda, M., Inamura, K., Togashi, Y., Hatano, S., Enomoto, M., Takada, S., Yamashita, Y., Satoh, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1018 · Cited by 502
The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non–Small Cell Lung Cancers
Tokumo, M., Toyooka, S., Kiura, K., Shigematsu, H., Tomii, K., Aoe, M., Ichimura, K., Tsuda, T., Yano, M., Tsukuda, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1167.11.3 · Cited by 490
EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers
Inamura, K., Takeuchi, K., Togashi, Y., Nomura, K., Ninomiya, H., Okui, M., Satoh, Y., Okumura, S., Nakagawa, K., Soda, M., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31815e8b60 · Cited by 467
Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung
Ahrendt, S. A., Decker, P. A., Alawi, E. A., Zhu, Y.-R., Sanchez-Cespedes, M., Yang, S. C., Haasler, G. B., Kajdacsy-Balla, A., Demeure, M. J., & Sidransky, D. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6<1525::aid-cncr1478>3.0.co;2-h · Cited by 449
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset
Inamura, K., Takeuchi, K., Togashi, Y., Hatano, S., Ninomiya, H., Motoi, N., Mun, M.-Y., Sakao, Y., Okumura, S., Nakagawa, K., et al. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.2 · Cited by 445
Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non–Small Cell Lung Cancer
Choi, Y. L., Takeuchi, K., Soda, M., Inamura, K., Togashi, Y., Hatano, S., Enomoto, M., Hamada, T., Haruta, H., Watanabe, H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6158 · Cited by 438
A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK -Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
Mino-Kenudson, M., Chirieac, L. R., Law, K., Hornick, J. L., Lindeman, N., Mark, E. J., Cohen, D. W., Johnson, B. E., Jänne, P. A., Iafrate, A. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2845 · Cited by 423
Self-citation
Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features
Tam, I. Y. S., Chung, L. P., Suen, W. S., Wang, E., Wong, M. C. M., Ho, K. K., Lam, W. K., Chiu, S. W., Girard, L., Minna, J. D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1981 · Cited by 400
Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors
McDermott, U., Iafrate, A. J., Gray, N. S., Shioda, T., Classon, M., Maheswaran, S., Zhou, W., Choi, H. G., Smith, S. L., Dowell, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6186 · Cited by 399
Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255
Tracy, S., Mukohara, T., Hansen, M., Meyerson, M., Johnson, B. E., & Jänne, P. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1905 · Cited by 374
The Nf2 Tumor Suppressor, Merlin, Functions in Rac-Dependent Signaling
Shaw, R. J., Paez, J. G., Curto, M., Yaktine, A., Pruitt, W. M., Saotome, I., O'Bryan, J. P., Gupta, V., Ratner, N., Der, C. J., et al. (2001) · Developmental Cell · doi:10.1016/s1534-5807(01)00009-0 · Cited by 343
Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene
Takahashi, T., Sonobe, M., Kobayashi, M., Yoshizawa, A., Menju, T., Nakayama, E., Mino, N., Iwakiri, S., Sato, K., Miyahara, R., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0808-7 · Cited by 326
EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues
Martelli, M. P., Sozzi, G., Hernandez, L., Pettirossi, V., Navarro, A., Conte, D., Gasparini, P., Perrone, F., Modena, P., Pastorino, U., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080755 · Cited by 317
Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non–Small Cell Lung Cancers
Lin, E., Li, L., Guan, Y., Soriano, R., Rivers, C. S., Mohan, S., Pandita, A., Tang, J., & Modrusan, Z. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0522 · Cited by 302
Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting
Eberhard, D. A., Giaccone, G., & Johnson, B. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9858 · Cited by 300
TRK-Fused Gene (TFG) Is a New Partner of ALK in Anaplastic Large Cell Lymphoma Producing Two Structurally DifferentTFG-ALK Translocations
Hernández, L., Pinyol, M., Hernández, S., Beà, S., Pulford, K., Rosenwald, A., Lamant, L., Falini, B., Ott, G., Mason, D. Y., et al. (1999) · Blood · doi:10.1182/blood.v94.9.3265 · Cited by 287
TP53 and KRAS Mutation Load and Types in Lung Cancers in Relation to Tobacco Smoke: Distinct Patterns in Never, Former, and Current Smokers
Le Calvez, F., Mukeria, A., Hunt, J. D., Kelm, O., Hung, R. J., Tanière, P., Brennan, P., Boffetta, P., Zaridze, D. G., & Hainaut, P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0551 · Cited by 273
EML4-ALK Fusion Lung Cancer: A Rare Acquired Event
Perner, S., Wagner, P. L., Demichelis, F., Mehra, R., LaFargue, C. J., Moss, B. J., Arbogast, S., Soltermann, A., Weder, W., Giordano, T. J., et al. (2008) · Neoplasia · doi:10.1593/neo.07878 · Cited by 249
Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066
Kwak, E. L., Camidge, D. R., Clark, J., Shapiro, G. I., Maki, R. G., Ratain, M. J., Solomon, B., Bang, Y., Ou, S., & Salgia, R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3509 · Cited by 207
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
Shih, J., Gow, C., Yu, C., Yang, C., Chang, Y., Tsai, M., Hsu, Y., Chen, K., Su, W., & Yang, P. (2006) · International Journal of Cancer · doi:10.1002/ijc.21458 · Cited by 170
EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas
Shinmura, K., Kageyama, S., Tao, H., Bunai, T., Suzuki, M., Kamo, T., Takamochi, K., Suzuki, K., Tanahashi, M., Niwa, H., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.12.013 · Cited by 164
Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients
Koivunen, J. P., Kim, J., Lee, J., Rogers, A. M., Park, J. O., Zhao, X., Naoki, K., Okamoto, I., Nakagawa, K., Yeap, B. Y., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604469 · Cited by 163
Self-citation
Clinicopathologic Significance of the Mutations of theEpidermal Growth Factor ReceptorGene in Patients with Non–Small Cell Lung Cancer
Tomizawa, Y., Iijima, H., Sunaga, N., Sato, K., Takise, A., Otani, Y., Tanaka, S., Suga, T., Saito, R., Ishizuka, T., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0441 · Cited by 131
Female Sex and Bronchioloalveolar Pathologic Subtype Predict EGFR Mutations in Non-small Cell Lung Cancer
Hsieh, R.-K., Lim, K., Kuo, H.-T., Tzen, C., & Huang, M.-J. (2005) · CHEST Journal · doi:10.1378/chest.128.1.317 · Cited by 120
Patterns of EGFR, HER2, TP53 , and KRAS Mutations of p14arf Expression in Non–Small Cell Lung Cancers in Relation to Smoking History
Mounawar, M., Mukeria, A., Calvez‐Kelm, F. L., Hung, R. J., Renard, H., Cortot, A. B., Bollart, C., Zaridze, D. G., Brennan, P., Boffetta, P., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4229 · Cited by 108
Epidermal Growth Factor Receptor Mutation in Lung Cancer are Linked to Bronchioloalveolar Differentiation
Blons, H., Côté, J.-F., Corre, D. L., Riquet, M., Fabre, E., Laurent‐Puig, P., & Danel, C. J. (2006) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213285.65907.31 · Cited by 93
EML4–ALK fusion transcript is not found in gastrointestinal and breast cancers
Fukuyoshi, Y., Inoue, H., Kita, Y., Utsunomiya, T., Ishida, T., & Mori, M. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604341 · Cited by 63

Lung cancer: Biology and treatment options
Lemjabbar-Alaoui, H., Hassan, O. U., Yang, Y.-W., & Buchanan, P. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.002 · Cited by 1,014
Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
Hammerman, P. S., Sos, M. L., Ramos, A. H., Xu, C., Dutt, A., Zhou, W., Brace, L. E., Woods, B. A., Lin, W., Zhang, J., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-11-0005 · Cited by 482
RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas
Bao, Z.-S., Chen, H.-M., Yang, M.-Y., Zhang, C.-B., Yu, K., Ye, W.-L., Hu, B.-Q., Yan, W., Zhang, W., Akers, J., et al. (2014) · Genome Research · doi:10.1101/gr.165126.113 · Cited by 409
Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer
Yoshida, T., Oya, Y., Tanaka, K., Shimizu, J., Horio, Y., Kuroda, H., Sakao, Y., Hida, T., & Yatabe, Y. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.8732 · Cited by 266
PROTAC therapy as a new targeted therapy for lung cancer
Li, J. W., Zheng, G., Kaye, F. J., & Wu, L. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.011 · Cited by 87

See all 555

Authors: Sasaki, T., Rodig, S. J., Chirieac, L. R., & Jänne, P. A.
Venue: European Journal of Cancer
Publisher: Elsevier BV
Published: 2010-07
Volume: 46
Issue: 10
Pages: 1773-1780
ISSN: 0959-8049 (ISSN-L)
DOI: 10.1016/j.ejca.2010.04.002
OpenAlex: W2094903176
Cited by: 555
References: 43
FWCI: 41.08
Type: journal article
Language: en
Open access: green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

The biology and treatment of EML4-ALK non-small cell lung cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources